热门资讯> 正文
爱德华兹完成对BD的单元出售，扩大股票回购
2024-09-05 00:31
- Edwards Life Sciences (NYSE:EW) announced it has completed the sale of its critical care business to Becton Dickinson (NYSE:BDX) for $4.2B in cash and expanded its stock buyback program.
- The medical device maker said its board has authorized an additional $1.5B for stock repurchases. Edwards recently entered into a $500M accelerated share repurchase agreement on top of $500M shares repurchased in August through a 10b5-1 agreement and open market repurchases.
- Edwards said that following the $1B repurchase, it has $1.4B remaining in its authorization, according to a statement.
More on Becton, Dickinson, Edwards Lifesciences, etc.
- Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy
- Becton, Dickinson and Company (BDX) Q3 2024 Earnings Call Transcript
- Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
- U.S. to restart free COVID test program as cases spike
- Becton, Dickinson slips as guidance disappoints
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
